secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2025-03-19T23:59:59+00:00
Accession:  0001764013-25-000037
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Batoclimab meets MG Phase 3 primary endpoint; CIDP shows 84% responder rate with >70% IgG reduction
--------------------------------------------------------------------------------

- MG Phase 3: 680mg batoclimab arm achieved 5.6-point MG-ADL improvement vs 3.6 placebo (p<0.001).
- Minimal Symptom Expression (MSE) at Week 12: 42% for 680mg, 31% for 340mg, 7% placebo.
- CIDP Phase 2b Period 1: 1.8-point aINCAT improvement; 84% responder rate among patients with ≥70% IgG reduction.
- Company will not seek batoclimab approval in MG/CIDP; focusing on IMVT-1402 and awaiting thyroid eye disease data.
- IND cleared for IMVT-1402 in MG and CIDP; registrational studies expected to start imminently.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000037/0001764013-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401325000037/imvt-20250319.htm
  HTML page:      https://secwatch.observer/filing/0001764013-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer